Related Experiment Videos
Sirolimus: a new option in transplantation
1Hospitais da Universidade de Coimbra, Praceta Prof. Mota Pinto, 3000-075 Coimbra, Portugal. afmota@iol.pt
Expert Opinion on Pharmacotherapy
|March 30, 2005
Summary
New immunosuppression strategies using sirolimus in renal transplantation improve graft and patient survival. Avoiding calcineurin inhibitors enhances renal function, offering hope for better long-term transplant outcomes.
Area of Science:
- Nephrology
- Immunology
- Transplantation Medicine
Background:
- Calcineurin inhibitors (CNIs) are standard immunosuppressants in renal transplantation.
- CNIs can cause nephrotoxicity, negatively impacting graft function and survival.
- Alternative immunosuppressive strategies are needed to mitigate CNI-related side effects.
Purpose of the Study:
- To review the role of sirolimus in renal transplantation.
- To evaluate novel immunosuppression strategies involving sirolimus.
- To assess the impact of these strategies on graft function and long-term outcomes.
Main Methods:
- Review of current literature on immunosuppression in renal transplantation.
- Analysis of studies employing sirolimus-based regimens.
- Comparison of outcomes between CNI-based and sirolimus-based protocols.
Main Results:
- Sirolimus-based immunosuppression, with or without reduced-dose CNIs, shows promise.
- Early CNI withdrawal or conversion to sirolimus can improve renal function.
- Year 1 graft and patient survival rates are favorable with these new strategies.
Conclusions:
- Novel sirolimus-based immunosuppression regimens offer improved renal function post-transplantation.
- These strategies hold potential for enhanced long-term graft survival and patient longevity.
- Reducing or eliminating calcineurin inhibitors is a viable approach in renal transplant immunosuppression.